Description: <b>Ferulic acid</b> is an antioxidant found in some skin creams and serums.<br>
Foods: popcorn, bamboo, whole-grain rye bread, whole-grain oat flakes, sweet corn (cooked)<br>
Ferulic acid (FA) is a
<a href="https://nestronics.ca/dbx/tbProdEdit.php?pid=95">hydroxycinnamic acid </a> abundant in plant cell walls (notably cereals/whole grains) with strong antioxidant and cytoprotective activity. Mechanistically, FA is frequently described as inducing Nrf2/HO-1 antioxidant programs and suppressing NF-κB-linked inflammation, with additional model-dependent anticancer effects (cell-cycle arrest, apoptosis, reduced invasion). Oral exposure is variable because FA is rapidly metabolized (often as conjugates) and bioaccessibility depends on the food matrix.<br>
<br>
-Ferulic acid found in dietary strand fractions, especially its free form, has important functions for protecting the human health.<br>
-AChE inhibitor (AD)<br>
-Cooking results in an increase in free ferulic acid quantity and in a reduction in bound ferulic acid quantity.<br>
<pre>
Bamboo shoots 243.6 mg/100g
Sugar-beet pulp 800 mg/100g
Popcorn 313 mg/100g
Wheat bran 500–1500mg/100g
Whole wheat flour 100–300mg/100g
</pre>
<table Border="1" rules="rows">
<tr><th>Type of corn</th> <th>p-coumaric acid</th> <th>ferulic acid</th></tr>
<tr><td> </td> <td> mg/kg, DW </td> <td>mg/kg, DW</td></tr>
<tr><td>Yellow dent</td> <td>18.9 </td> <td>265</td></tr>
<tr><td>American blue</td> <td>N.D. </td> <td>927</td></tr>
<tr><td>Mexican blue</td> <td>1.3 </td> <td>202</td></tr>
<tr><td>white</td> <td>6.6 </td> <td>2484</td></tr>
</table>
<pre>
Pathway / Target Modulation by FA / Direction
Aβ aggregation ↓ Inhibits fibril formation and destabilizes existing Aβ fibrils
BACE‑1 & APP ↓ Reduces BACE-1 and APP expression; ↑ MMP‑2/‑9 expression promoting Aβ clearance
Tau hyperphosphorylation Implicitly ↓ through modulation of Ca²⁺/CDK5/GSK3β pathways
Ca²⁺ ↓ FA lowers STEP levels via chelation of Ca²⁺, suppressing PP2B → restores synaptic plasticity
(AChE / BChE) ↓ Inhibition of AChE (FA IC₅₀~15 µM, derivatives IC₅₀ down to 0.006 µM); also BChE
(MAO‑A/B) ↓ Inhibits MAO‑B (derivatives IC₅₀ ~0.3–0.7 µM), reducing ROS
ROS ↓ Scavenges ROS, enhances antioxidant enzymes (e.g., catalase), ↓ MDA
(COX‑2, 5‑LOX, NLRP3) ↓ Derivatives inhibit COX‑2/5‑LOX; derivative 13a ↓ NLRP3 inflammasome
Iron/Cu²⁺ chelation ↓ Metal-induced Aβ aggregation via chelation by FA and derivatives
Autophagy & Aβ clearance ↗ Suggested promotion of autophagy mechanisms targeting Aβ
</pre>
<br>
<p><b>Ferulic acid</b> — Ferulic acid is a naturally occurring hydroxycinnamic phenolic acid concentrated in plant cell walls, particularly in cereal bran, whole grains, rice bran, corn, oats, wheat, bamboo shoots, and some fruits and vegetables. It is formally classified as a dietary polyphenol and phenolic antioxidant; the standard abbreviation is FA. Most food-derived FA is ester-linked to arabinoxylans, lignin, and other structural polysaccharides, whereas free FA is more readily absorbed. FA has predominantly antioxidant and cytoprotective activity in normal tissues, but can produce antiproliferative, pro-oxidant, mitochondrial, apoptotic, pyroptotic, and anti-invasive effects in susceptible cancer models. It is not an approved anticancer drug.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of cancer-cell growth arrest and mitochondrial cell death through suppression of PI3K/AKT/mTOR, STAT3, cyclins, and CDKs, with activation of p53, p21, BAX, caspases, and related stress pathways.</li>
<li>Context-dependent redox disruption in cancer cells, including ROS accumulation, glutathione and antioxidant-enzyme depletion, mitochondrial dysfunction, lipid peroxidation, and ROS/JNK/BAX-dependent apoptosis or pyroptosis.</li>
<li>Suppression of EMT, migration, invasion, angiogenesis, and metastasis through modulation of MMP2, MMP9, VEGF, β-catenin/ZEB1, vimentin, E-cadherin, NF-κB, and related pathways.</li>
<li>Inhibition of glycolytic and anabolic signalling, including reductions in c-MYC, PKM2, LDH, CAIX, PI3K/AKT/mTOR, and tumor-associated glycolysis in selected models.</li>
<li>Modulation of DNA-damage responses and cell-cycle checkpoints, including ATM, ATR, CHK1/2, γH2AX, p53, p21, CDC25, CDK2, CDK4/6, and cyclin D1.</li>
<li>Suppression of tumor-promoting inflammatory signalling, particularly NF-κB, COX-2, JAK2/STAT3, inflammatory cytokines, and related mediators.</li>
<li>NRF2/HO-1 and direct radical-scavenging activity are central to normal-cell protection but are secondary and context-dependent in cancer, where antioxidant signalling could theoretically protect some tumors from oxidative therapies.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Orally administered FA is absorbed from the stomach and small intestine, with additional release and microbial conversion of cereal-bound FA in the colon. It undergoes rapid first-pass glucuronidation, sulfation, methylation, and glycine conjugation; circulating material is predominantly conjugated rather than free FA. Food-matrix binding is a major constraint: free FA and processed or enzymatically released FA are more bioavailable than intact bran-bound FA. Human cereal studies have reported free or equivalent plasma concentrations in the low-nanomolar range, while pharmacokinetic results from herbal mixtures cannot be directly extrapolated to purified FA. Nanoencapsulation, phospholipid carriers, ester derivatives, and enzymatic liberation from bran can increase exposure experimentally, but none is established for oncology.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer experiments use approximately 25–500 µM FA, with many cytotoxic effects occurring at 100 µM or higher. These concentrations substantially exceed the low-nanomolar free FA levels typically observed after ordinary dietary intake and likely exceed sustained free systemic exposure achievable with conventional oral preparations. Therefore, direct systemic tumor cytotoxicity from dietary FA is pharmacokinetically implausible. Local gastrointestinal exposure, metabolites, repeated dosing, formulated delivery, or pharmacological derivatives may be more relevant than plasma free-FA concentrations.</p>
<p><b>Clinical evidence status:</b> Cancer evidence is preclinical, consisting mainly of cultured cancer cells and rodent xenograft or carcinogenesis models. There are no established oncology RCTs showing tumor response, progression-free survival, or overall-survival benefit from purified FA. Radiosensitization and chemosensitization have been reported experimentally, but FA also protects normal tissues from radiation and chemotherapy injury; the net interaction is treatment-, timing-, dose-, and tissue-dependent. Human evidence is limited mainly to dietary bioavailability, topical dermatology, cardiovascular or metabolic observations, and combination supplements studied in cognitive impairment. FA should not be classified as a clinically validated anticancer therapy.</p>
<h3>Ferulic Acid Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>PI3K AKT mTOR survival signalling</td>
<td>PI3K ↓; AKT ↓; mTOR ↓; PTEN ↑ (model-dependent)</td>
<td>AKT ↔ or ↑ during injury protection</td>
<td>R, G</td>
<td>Growth inhibition and apoptosis sensitization</td>
<td>A recurrent anticancer axis, although direction in normal stressed tissue may differ from that in malignant cells.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis</td>
<td>Mitochondrial membrane potential ↓; BAX ↑; BCL-2 ↓; cytochrome c release ↑; caspase-9 ↑; caspase-3 ↑; apoptosis ↑</td>
<td>Mitochondrial injury ↓; apoptosis ↓ under toxic or inflammatory stress</td>
<td>R, G</td>
<td>Intrinsic cell-death execution</td>
<td>Common downstream phenotype in susceptible cancer models; frequently concentration- and cell-line-dependent.</td>
</tr>
<tr>
<td>3</td>
<td>Cancer-cell ROS and pyroptotic stress</td>
<td>ROS ↑; JNK ↑; BAX ↑; GSDMD processing ↑; apoptosis or pyroptosis ↑ (model-dependent)</td>
<td>ROS ↓; lipid peroxidation ↓; oxidative injury ↓</td>
<td>P, R, G</td>
<td>Selective redox overload</td>
<td>FA is not uniformly antioxidant in cancer. A ROS/JNK/BAX/GSDMD mechanism has been reported in lung-cancer models, but is not established across tumor types.</td>
</tr>
<tr>
<td>4</td>
<td>Cell-cycle checkpoint control</td>
<td>p53 ↑; p21 ↑; CHK1/2 ↑; CDC25 ↓; CDK2 ↓; CDK4/6 ↓; cyclin D1 ↓; arrest ↑</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>The specific arrest phase varies among models and may include G0/G1, S-phase, or G2/M accumulation.</td>
</tr>
<tr>
<td>5</td>
<td>EMT invasion and metastasis</td>
<td>EMT ↓; MMP2 ↓; MMP9 ↓; vimentin ↓; β-catenin/ZEB1 ↓; migration ↓; invasion ↓</td>
<td>↔</td>
<td>G</td>
<td>Anti-invasive and antimetastatic phenotype</td>
<td>Supported principally by cell migration assays and animal tumor models rather than clinical evidence.</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB inflammatory signalling</td>
<td>NF-κB ↓; COX-2 ↓; inflammatory cytokines ↓; survival signalling ↓</td>
<td>NF-κB ↓; COX-2 ↓; iNOS ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓</td>
<td>R, G</td>
<td>Reduced inflammation and tumor-promoting signalling</td>
<td>This mechanism is more consistently protective and anti-inflammatory than directly cytotoxic.</td>
</tr>
<tr>
<td>7</td>
<td>Glycolysis and anabolic metabolism</td>
<td>c-MYC ↓; PKM2 ↓; LDH ↓; CAIX ↓; glycolysis ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Metabolic growth restriction</td>
<td>Potentially important in highly glycolytic tumors but supported by fewer models than apoptosis and cell-cycle regulation.</td>
</tr>
<tr>
<td>8</td>
<td>STAT and growth-factor signalling</td>
<td>JAK2 ↓; phosphorylated STAT3 ↓; STAT6 ↓; FGFR1 ↓; FGFR2 ↓; proliferation ↓</td>
<td>↔</td>
<td>R, G</td>
<td>Suppression of proliferative transcription</td>
<td>Individual targets are tumor-model-specific and should not be treated as universal direct molecular targets of FA.</td>
</tr>
<tr>
<td>9</td>
<td>Angiogenesis</td>
<td>VEGF ↓; angiogenesis ↓</td>
<td>VEGF ↔ or ↑ during tissue repair (context-dependent)</td>
<td>G</td>
<td>Reduced tumor vascular support</td>
<td>Potentially opposite modulation in ischemic or reparative normal tissue illustrates the context dependence of FA.</td>
</tr>
<tr>
<td>10</td>
<td>DNA damage response</td>
<td>ATM ↑; ATR ↑; CHK1/2 ↑; γH2AX ↑; DNA damage ↑ (high concentration only)</td>
<td>DNA oxidative damage ↓</td>
<td>R, G</td>
<td>Checkpoint activation and tumor-cell death</td>
<td>At pharmacological concentrations, FA may promote cancer-cell stress while protecting normal DNA through antioxidant activity.</td>
</tr>
<tr>
<td>11</td>
<td>NRF2 HO-1 antioxidant response</td>
<td>NRF2 ↔ or ↑ (context-dependent); possible tumor stress adaptation</td>
<td>NRF2 ↑; ARE ↑; HO-1 ↑; NQO1 ↑; GCLC ↑; GCLM ↑; GSH ↑</td>
<td>R, G</td>
<td>Endogenous antioxidant defence</td>
<td>A core cytoprotective mechanism in normal tissues but not necessarily therapeutically favourable in NRF2-dependent tumors.</td>
</tr>
<tr>
<td>12</td>
<td>Mitochondrial dynamics and tissue protection</td>
<td>Not consistently defined</td>
<td>DRP1 ↓; FIS1 ↓; MFN1 ↑; MFN2 ↑; OPA1 ↑; mitochondrial damage ↓</td>
<td>R, G</td>
<td>Preservation of mitochondrial integrity</td>
<td>Reported mainly in toxic, metabolic, cardiovascular, or neurological injury models.</td>
</tr>
<tr>
<td>13</td>
<td>Radiosensitization and radioprotection</td>
<td>Radiosensitization ↑ in selected models; DNA damage and apoptosis ↑ (model-dependent)</td>
<td>Radiation-induced ROS ↓; inflammation ↓; tissue injury ↓; radioprotection ↑</td>
<td>R, G</td>
<td>Bidirectional radiation interaction</td>
<td>Timing and tissue selectivity are critical. Normal-tissue radioprotection does not establish improved tumor control and could theoretically reduce efficacy under some conditions.</td>
</tr>
<tr>
<td>14</td>
<td>Chemosensitization and treatment toxicity</td>
<td>Chemosensitivity ↑ in selected drug and cell-line combinations</td>
<td>Chemotherapy-associated oxidative or inflammatory injury ↓</td>
<td>R, G</td>
<td>Adjunct modulation</td>
<td>No standardized human oncology dosing or validated treatment combination has been established.</td>
</tr>
<tr>
<td>15</td>
<td>Clinical Translation Constraint</td>
<td>Free systemic FA exposure is far below many cytotoxic in-vitro concentrations</td>
<td>Rapid conjugation; matrix-dependent absorption; generally dietary exposure</td>
<td>—</td>
<td>Limited systemic anticancer translation</td>
<td>Most experiments use tens to hundreds of micromolar FA, whereas human dietary exposure produces predominantly conjugated metabolites and low free plasma concentrations.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<p><b>Alzheimer’s disease relevance:</b> Ferulic acid has substantial preclinical relevance to Alzheimer’s disease through direct inhibition of amyloid-β aggregation, attenuation of APP and BACE1 processing, reduction of tau phosphorylation, suppression of neuroinflammation and oxidative injury, metal chelation, preservation of mitochondrial function, and modulation of cholinergic signalling. FA and several FA-derived multifunctional compounds inhibit AChE or BChE in vitro, but the potency of derivatives should not be attributed to unmodified FA. Small human studies have evaluated combination products containing FA and Angelica archangelica extract in mild cognitive impairment or dementia-related symptoms; these do not establish efficacy of isolated FA or demonstrate disease modification. The clinical evidence remains preliminary and formulation-specific.</p>
<p><b>AD clinical evidence status:</b> Strong preclinical evidence; limited small human combination-product studies; no confirmatory phase III trial; no regulatory approval for prevention or treatment of Alzheimer’s disease. Reported cognitive findings require replication using isolated FA, adequate sample sizes, biomarker-defined populations, validated dosing, and longer follow-up.</p>
<h3>Ferulic Acid in Alzheimer’s Disease</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Amyloid beta aggregation</td>
<td>Aβ oligomerization ↓; fibril formation ↓; existing fibril stability ↓</td>
<td>P, R</td>
<td>Reduced amyloid aggregation</td>
<td>Direct anti-aggregation effects are demonstrated mainly in biochemical and cellular systems at concentrations not clearly achieved in human brain tissue.</td>
</tr>
<tr>
<td>2</td>
<td>APP BACE1 amyloid production</td>
<td>APP ↓; BACE1 ↓; amyloidogenic processing ↓</td>
<td>G</td>
<td>Reduced Aβ generation</td>
<td>Supported mainly by cellular and animal models.</td>
</tr>
<tr>
<td>3</td>
<td>Oxidative stress and NRF2 HO-1</td>
<td>ROS ↓; lipid peroxidation ↓; NRF2 ↑; HO-1 ↑; NQO1 ↑; GSH ↑; antioxidant enzymes ↑</td>
<td>P, R, G</td>
<td>Neuronal redox protection</td>
<td>One of the most consistent neuroprotective mechanisms across toxicant and neurodegeneration models.</td>
</tr>
<tr>
<td>4</td>
<td>Neuroinflammation</td>
<td>NF-κB ↓; NLRP3 ↓; COX-2 ↓; iNOS ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓</td>
<td>R, G</td>
<td>Reduced inflammatory neuronal injury</td>
<td>Predominantly demonstrated in animal and glial-cell models.</td>
</tr>
<tr>
<td>5</td>
<td>Tau kinase and phosphatase balance</td>
<td>GSK3β activity ↓; CDK5 dysregulation ↓; tau hyperphosphorylation ↓ (model-dependent)</td>
<td>R, G</td>
<td>Reduced tau pathology</td>
<td>The exact upstream mechanism varies and may involve calcium signalling, AKT, ERK, and oxidative-stress regulation.</td>
</tr>
<tr>
<td>6</td>
<td>Cholinergic signalling</td>
<td>AChE ↓; BChE ↓; acetylcholine availability ↑; ChAT ↑ (model-dependent)</td>
<td>P, R, G</td>
<td>Improved cholinergic transmission</td>
<td>Unmodified FA is generally less potent than optimized FA derivatives; derivative potency must be recorded separately.</td>
</tr>
<tr>
<td>7</td>
<td>Mitochondrial function</td>
<td>Mitochondrial ROS ↓; membrane-potential loss ↓; ATP preservation ↑; DRP1 ↓; FIS1 ↓; MFN1 and MFN2 ↑</td>
<td>R, G</td>
<td>Preserved neuronal bioenergetics</td>
<td>Evidence derives mainly from oxidative, toxicant, and ischemic injury models.</td>
</tr>
<tr>
<td>8</td>
<td>Calcium dependent synaptic dysfunction</td>
<td>Pathological Ca²⁺ signalling ↓; calcineurin PP2B signalling ↓; STEP ↓ (model-dependent)</td>
<td>P, R</td>
<td>Preserved synaptic plasticity</td>
<td>The description of FA as directly chelating neuronal calcium should be used cautiously; pathway modulation is better supported than clinically meaningful systemic calcium chelation.</td>
</tr>
<tr>
<td>9</td>
<td>Metal associated amyloid toxicity</td>
<td>Iron and Cu²⁺ coordination ↑; metal-driven ROS and Aβ aggregation ↓</td>
<td>P, R</td>
<td>Reduced metal-mediated oxidative aggregation</td>
<td>Most evidence is biochemical. Brain exposure sufficient for clinically meaningful chelation has not been established.</td>
</tr>
<tr>
<td>10</td>
<td>Autophagy and proteostasis</td>
<td>Autophagic clearance ↔ or ↑ (model-dependent); Aβ clearance ↑</td>
<td>G</td>
<td>Improved aggregate disposal</td>
<td>Autophagy findings are inconsistent and should not be represented as a universal FA mechanism.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Brain exposure uncertain; extensive conjugation; human evidence derived largely from combination products</td>
<td>—</td>
<td>Unproven disease modification</td>
<td>No validated isolated-FA dose, target-engagement biomarker, or confirmatory Alzheimer’s disease trial is available.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>